| Bronstein, Gewirtz & Grossman, LLC Is Investigating PTC Therapeutics, Inc. (PTCT) And Encourages Investors to Connect |
NEW YORK CITY, NY / ACCESS Newswire / May 16, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of PTC Therapeutics, Inc. ("PTC" or "the Company") (NASDAQ:PTCT). Investors who purchased PTC securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/PTCT. |
accessnewswire.com |
2025-05-16 14:00:00 |
Czytaj oryginał (ang.) |
| INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT |
NEW YORK CITY, NY / ACCESS Newswire / May 16, 2025 / Pomerantz LLP is investigating claims on behalf of investors of PTC Therapeutics, Inc. ("PTC" or the "Company") (NASDAQ:PTCT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
accessnewswire.com |
2025-05-16 13:00:00 |
Czytaj oryginał (ang.) |
| Bronstein, Gewirtz & Grossman, LLC Encourages PTC Therapeutics, Inc. (PTCT) Stockholders to Inquire about Securities Investigation |
NEW YORK CITY, NY / ACCESS Newswire / May 15, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of PTC Therapeutics, Inc. ("PTC" or "the Company") (NASDAQ:PTCT). Investors who purchased PTC securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/PTCT. |
accessnewswire.com |
2025-05-15 14:00:00 |
Czytaj oryginał (ang.) |
| Lost Money on PTC Therapeutics, Inc. (PTCT)? Possible Fraud - Contact Levi & Korsinsky Today |
NEW YORK, NY / ACCESS Newswire / May 14, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of PTC Therapeutics, Inc. ("PTC Therapeutics, Inc.") (NASDAQ:PTCT) concerning possible violations of federal securities laws. PTC issued a press release on May 5, 2025, "announc[ing] results from the Phase 2 PIVOT-HD study of PTC518 (votoplam) in Stage 2 and Stage 3 Huntington's disease (HD) patients. |
accessnewswire.com |
2025-05-14 14:30:00 |
Czytaj oryginał (ang.) |
| Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against PTC Therapeutics, Inc. (PTCT) and Encourages Investors to Learn More About the Investigation |
NEW YORK CITY, NY / ACCESS Newswire / May 14, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of PTC Therapeutics, Inc. ("PTC" or "the Company") (NASDAQ:PTCT). Investors who purchased PTC securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/PTCT. |
accessnewswire.com |
2025-05-14 14:00:00 |
Czytaj oryginał (ang.) |
| INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT |
NEW YORK, NY / ACCESS Newswire / May 14, 2025 / Pomerantz LLP is investigating claims on behalf of investors of PTC Therapeutics, Inc. ("PTC" or the "Company") (NASDAQ:PTCT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
accessnewswire.com |
2025-05-14 13:00:00 |
Czytaj oryginał (ang.) |
| Did PTC Therapeutics, Inc. Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky Investigate - PTCT |
NEW YORK, NY / ACCESS Newswire / May 13, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of PTC Therapeutics, Inc. ("PTC Therapeutics, Inc.") (NASDAQ:PTCT) concerning possible violations of federal securities laws. PTC issued a press release on May 5, 2025, "announc[ing] results from the Phase 2 PIVOT-HD study of PTC518 (votoplam) in Stage 2 and Stage 3 Huntington's disease (HD) patients. |
accessnewswire.com |
2025-05-13 16:25:00 |
Czytaj oryginał (ang.) |
| Shareholders that lost money on PTC Therapeutics, Inc. (PTCT) should contact Levi & Korsinsky about Securities Fraud Investigation - PTCT |
NEW YORK, NY / ACCESS Newswire / May 13, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of PTC Therapeutics, Inc. ("PTC Therapeutics, Inc.") (NASDAQ:PTCT) concerning possible violations of federal securities laws. PTC issued a press release on May 5, 2025, "announc[ing] results from the Phase 2 PIVOT-HD study of PTC518 (votoplam) in Stage 2 and Stage 3 Huntington's disease (HD) patients. |
accessnewswire.com |
2025-05-13 14:15:00 |
Czytaj oryginał (ang.) |
| PTC Therapeutics, Inc. (PTCT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation |
NEW YORK CITY, NY / ACCESS Newswire / May 13, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of PTC Therapeutics, Inc. ("PTC" or "the Company") (NASDAQ:PTCT). Investors who purchased PTC securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/PTCT. |
accessnewswire.com |
2025-05-13 14:00:00 |
Czytaj oryginał (ang.) |
| Investors Who Lost Money on PTC Therapeutics, Inc. Should Contact Levi & Korsinsky About an Ongoing Investigation - PTCT |
NEW YORK, NY / ACCESS Newswire / May 12, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of PTC Therapeutics, Inc. ("PTC Therapeutics, Inc.") (NASDAQ:PTCT) concerning possible violations of federal securities laws. PTC issued a press release on May 5, 2025, "announcing results from the Phase 2 PIVOT-HD study of PTC518 (votoplam) in Stage 2 and Stage 3 Huntington's disease (HD) patients. |
accessnewswire.com |
2025-05-12 21:30:00 |
Czytaj oryginał (ang.) |
| INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT |
NEW YORK , May 12, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of PTC Therapeutics, Inc. ("PTC" or the "Company") (NASDAQ: PTCT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
prnewswire.com |
2025-05-12 21:07:00 |
Czytaj oryginał (ang.) |
| Shareholders that lost money on PTC Therapeutics, Inc. (PTCT) should contact Levi & Korsinsky about Securities Fraud Investigation - PTCT |
NEW YORK, NY / ACCESS Newswire / May 12, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of PTC Therapeutics, Inc. ("PTC Therapeutics, Inc.") (NASDAQ:PTCT) concerning possible violations of federal securities laws. PTC issued a press release on May 5, 2025, "announc[ing] results from the Phase 2 PIVOT-HD study of PTC518 (votoplam) in Stage 2 and Stage 3 Huntington's disease (HD) patients. |
accessnewswire.com |
2025-05-12 14:30:00 |
Czytaj oryginał (ang.) |
| Bronstein, Gewirtz & Grossman, LLC Is Investigating PTC Therapeutics, Inc. (PTCT) And Encourages Investors to Connect |
NEW YORK CITY, NY / ACCESS Newswire / May 12, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of PTC Therapeutics, Inc. ("PTC" or "the Company") (NASDAQ:PTCT). Investors who purchased PTC securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/PTCT. |
accessnewswire.com |
2025-05-12 14:00:00 |
Czytaj oryginał (ang.) |
| PTC Therapeutics, Inc. Investigated Regarding Potential Securities Law Violations - Contact Levi & Korsinsky for Details- PTCT |
NEW YORK, NY / ACCESS Newswire / May 11, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of PTC Therapeutics, Inc. ("PTC Therapeutics, Inc.") (NASDAQ:PTCT) concerning possible violations of federal securities laws. PTC issued a press release on May 5, 2025, "announc[ing] results from the Phase 2 PIVOT-HD study of PTC518 (votoplam) in Stage 2 and Stage 3 Huntington's disease (HD) patients. |
accessnewswire.com |
2025-05-11 15:00:00 |
Czytaj oryginał (ang.) |
| Bronstein, Gewirtz & Grossman, LLC Is Investigating PTC Therapeutics, Inc. (PTCT) And Encourages Stockholders to Connect |
NEW YORK CITY, NY / ACCESS Newswire / May 11, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of PTC Therapeutics, Inc. ("PTC" or "the Company") (NASDAQ:PTCT). Investors who purchased PTC securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/PTCT. |
accessnewswire.com |
2025-05-11 14:00:00 |
Czytaj oryginał (ang.) |
| Shareholder Rights Advocates at Levi & Korsinsky Investigate PTC Therapeutics, Inc. (PTCT) Regarding Possible Securities Fraud Violations |
NEW YORK, NY / ACCESS Newswire / May 10, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of PTC Therapeutics, Inc. ("PTC Therapeutics, Inc.") (NASDAQ:PTCT) concerning possible violations of federal securities laws. PTC issued a press release on May 5, 2025, "announc[ing] results from the Phase 2 PIVOT-HD study of PTC518 (votoplam) in Stage 2 and Stage 3 Huntington's disease (HD) patients. |
accessnewswire.com |
2025-05-10 22:01:00 |
Czytaj oryginał (ang.) |
| INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT |
NEW YORK CITY, NY / ACCESS Newswire / May 10, 2025 / Pomerantz LLP is investigating claims on behalf of investors of PTC Therapeutics, Inc. ("PTC" or the "Company") (NASDAQ:PTCT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
accessnewswire.com |
2025-05-10 12:00:00 |
Czytaj oryginał (ang.) |
| Lost Money on PTC Therapeutics, Inc. (PTCT)? Contact Levi & Korsinsky Regarding an Ongoing Investigation |
NEW YORK, NY / ACCESS Newswire / May 9, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of PTC Therapeutics, Inc. ("PTC Therapeutics, Inc.") (NASDAQ:PTCT) concerning possible violations of federal securities laws. PTC issued a press release on May 5, 2025, "announc[ing] results from the Phase 2 PIVOT-HD study of PTC518 (votoplam) in Stage 2 and Stage 3 Huntington's disease (HD) patients. |
accessnewswire.com |
2025-05-09 14:55:00 |
Czytaj oryginał (ang.) |
| INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT |
NEW YORK, May 09, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of PTC Therapeutics, Inc. (“PTC” or the “Company”) (NASDAQ: PTCT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. |
globenewswire.com |
2025-05-09 14:37:00 |
Czytaj oryginał (ang.) |
| Shareholders Who Lost Money on PTC Therapeutics, Inc. (PTCT) Should Contact Levi & Korsinsky About Securities Fraud Investigation - PTCT |
NEW YORK, NY / ACCESS Newswire / May 9, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of PTC Therapeutics, Inc. ("PTC Therapeutics, Inc.") (NASDAQ:PTCT) concerning possible violations of federal securities laws. PTC issued a press release on May 5, 2025, "announc[ing] results from the Phase 2 PIVOT-HD study of PTC518 (votoplam) in Stage 2 and Stage 3 Huntington's disease (HD) patients. |
accessnewswire.com |
2025-05-09 14:15:00 |
Czytaj oryginał (ang.) |
| PTC Therapeutics (PTCT) Reports Q4 Earnings: What Key Metrics Have to Say |
Although the revenue and EPS for PTC Therapeutics (PTCT) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers. |
zacks.com |
2025-02-27 20:31:08 |
Czytaj oryginał (ang.) |
| PTC Therapeutics (PTCT) Reports Q4 Loss, Lags Revenue Estimates |
PTC Therapeutics (PTCT) came out with a quarterly loss of $0.24 per share versus the Zacks Consensus Estimate of a loss of $0.96. This compares to loss of $0.24 per share a year ago. |
zacks.com |
2025-02-27 20:15:29 |
Czytaj oryginał (ang.) |
| PTC Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results |
– Full year 2024 revenue of $807 million, exceeding guidance – – All 2024 clinical and regulatory milestones were achieved on schedule, including four NDA submissions, all of which were accepted for filing – – License and collaboration agreement with Novartis for PTC518 Huntington's disease program closed in January 2025 – – Cash of over $2.0 billion as of January 2025 – WARREN, N.J. , Feb. 27, 2025 /PRNewswire/ -- PTC Therapeutics, Inc., (NASDAQ: PTCT) today announced a corporate update and financial results for the fourth quarter ending December 31, 2024. |
prnewswire.com |
2025-02-27 18:01:00 |
Czytaj oryginał (ang.) |
| Countdown to PTC Therapeutics (PTCT) Q4 Earnings: A Look at Estimates Beyond Revenue and EPS |
Besides Wall Street's top -and-bottom-line estimates for PTC Therapeutics (PTCT), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2024. |
zacks.com |
2025-02-24 12:22:02 |
Czytaj oryginał (ang.) |
| PTC Therapeutics (PTCT) Expected to Beat Earnings Estimates: Can the Stock Move Higher? |
PTC Therapeutics (PTCT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
zacks.com |
2025-02-20 13:06:13 |
Czytaj oryginał (ang.) |
| PTC Therapeutics to Participate in Upcoming Investor Conferences |
WARREN, N.J. , Feb. 20, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that its executives will participate in fireside chats at the following investor conferences: TD Cowen 45th Annual Health Care 2025 Conference Tuesday, March 4 at 11:10 a.m. |
prnewswire.com |
2025-02-20 10:00:00 |
Czytaj oryginał (ang.) |
| PTC Therapeutics Announces FDA Acceptance and Priority Review for Vatiquinone NDA for the Treatment of Children and Adults with Friedreich's Ataxia |
- PDUFA target action date of Aug. 19, 2025 - WARREN, N.J. , Feb. 19, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the U.S. Food and Drug Administration (FDA) has accepted for filing the New Drug Application (NDA) for vatiquinone for the treatment of children and adults living with Friedreich's ataxia (FA). |
prnewswire.com |
2025-02-19 09:00:00 |
Czytaj oryginał (ang.) |
| PTC Therapeutics to Host Conference Call to Discuss Fourth Quarter and Full Year 2024 Financial Results |
WARREN, N.J. , Feb. 13, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will host a webcast conference call to report its fourth quarter and full year 2024 financial results and provide an update on the company's business and outlook on Thursday, Feb. 27, at 4:30 p.m. |
prnewswire.com |
2025-02-13 10:00:00 |
Czytaj oryginał (ang.) |
| PTC Therapeutics (PTCT) Moves 9.0% Higher: Will This Strength Last? |
PTC Therapeutics (PTCT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term. |
zacks.com |
2025-02-04 08:06:08 |
Czytaj oryginał (ang.) |
| PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
WARREN, N.J. , Jan. 13, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on Jan. 3, 2025, the company approved 1,200 restricted stock units ("RSUs"), each representing the right to receive one share of its common stock upon vesting, to two new employees. |
prnewswire.com |
2025-01-13 18:30:00 |
Czytaj oryginał (ang.) |
| PTC Therapeutics Provides Update on Commercial Performance and R&D Pipeline at 43rd Annual J.P. Morgan Healthcare Conference |
– Unaudited 2024 total revenue of approximately $814 million, exceeding guidance – – Four approval applications submitted to FDA in 2024 – – Global launch preparations underway for sepiapterin for PKU, a $1 billion market opportunity; CHMP opinion expected Q2 2025, U.S. approval decision in July 2025 – – License and collaboration agreement with Novartis for PTC518 program closed – – PIVOT-HD data readout for PTC518 expected Q2 2025 – WARREN, N.J. , Jan. 13, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today provided an update on the Company's progress and its outlook for 2025. |
prnewswire.com |
2025-01-13 11:00:00 |
Czytaj oryginał (ang.) |
| PTC Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference |
WARREN, N.J. , Dec. 23, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that CEO Matthew B. |
prnewswire.com |
2024-12-23 10:00:00 |
Czytaj oryginał (ang.) |
| PTC Therapeutics Announces Vatiquinone NDA Submission to FDA for the Treatment of Children and Adults Living with Friedreich Ataxia |
- If approved, vatiquinone would be the first and only authorized therapy for children with FA - - PTC's fourth approval application submitted to FDA in 2024 - WARREN, N.J. , Dec. 19, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today the submission of the vatiquinone New Drug Application (NDA) for the treatment of children and adults living with Friedreich ataxia (FA) to the U.S. Food and Drug Administration (FDA). |
prnewswire.com |
2024-12-19 10:00:00 |
Czytaj oryginał (ang.) |
| PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
WARREN, N.J. , Dec. 17, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on Dec. 13, 2024, the company approved non-statutory stock options to purchase an aggregate of 1,725 shares of its common stock and 5,060 restricted stock units ("RSUs"), each representing the right to receive one share of its common stock upon vesting, to eight new employees. |
prnewswire.com |
2024-12-17 18:30:00 |
Czytaj oryginał (ang.) |
| PTCT Stock Soars on Licensing Deal With NVS for Huntington's Therapy |
Per the terms, PTC will receive $1 billion in upfront payment from Novartis upon the deal's closure. It is also eligible for milestone payments of up to $1.9 billion. |
zacks.com |
2024-12-03 16:40:28 |
Czytaj oryginał (ang.) |
| PTC Therapeutics price target raised to $56 from $45 at Barclays |
Barclays raised the firm's price target on PTC Therapeutics to $56 from $45 and keeps an Equal Weight rating on the shares. The company's deal with Novartis is favorable with high upfront payment and milestones, the analyst tells investors in a research note. The deal strengthens PTC's balance sheet and validates its platform, but transfers development risk, says the firm. |
https://thefly.com |
2024-12-03 07:53:26 |
Czytaj oryginał (ang.) |
| PTC Therapeutics Stock Soars on Novartis Licensing Agreement |
Shares of PTC Therapeutics (PTCT) soared 16% Monday when the pharmaceutical firm announced it struck a nearly $2 billion license and collaboration deal with Novartis (NVS). |
investopedia.com |
2024-12-02 15:50:44 |
Czytaj oryginał (ang.) |
| PTC Therapeutics Inks Licensing Pact With Novartis Worth Up To ~$3 Billion For Huntington's Program |
On Monday, PTC Therapeutics, Inc. PTCT signed an exclusive global license and collaboration agreement with Novartis AG NVS for its PTC518 Huntington's disease program, which includes related molecules. |
benzinga.com |
2024-12-02 14:58:49 |
Czytaj oryginał (ang.) |
| PTC Therapeutics Scores A $2.9 Billion Novartis Deal And Hits Profit-Taking Zone |
Novartis will pay PTC Therapeutics up to $2.9 billion in a licensing deal for its Huntington's treatment. PTC Therapeutics stock surged. |
investors.com |
2024-12-02 11:32:47 |
Czytaj oryginał (ang.) |
| PTC Therapeutics signs up to $1.9 billion licensing deal with Novartis |
PTC Therapeutics has entered into a licensing deal with a unit of Novartis AG for up to $1.9 billion, the company said on Monday, for its experimental drug being developed for a rare neurological disorder. |
reuters.com |
2024-12-02 09:14:56 |
Czytaj oryginał (ang.) |
| PTC Therapeutics Enters into a Global License and Collaboration Agreement with Novartis for PTC518 Huntington's Disease Program |
- PTC to receive $1.0B in cash at closing - - PTC is eligible to receive up to $1.9B in development, regulatory and sales milestones - - PTC to share profits in the U.S. and tiered double-digit royalties on ex-U.S. net sales - - Novartis will assume global development, manufacturing and commercial responsibilities following completion of placebo-controlled portion of ongoing PIVOT-HD study - - PTC will host a conference call on Dec. 2, 2024, at 8:30 am EST- WARREN, N.J. , Dec. 2, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today the signing of an exclusive global license and collaboration agreement with Novartis Pharmaceuticals Corporation, a subsidiary of Novartis AG (NYSE: NVS), for its PTC518 Huntington's disease program, which includes related molecules. |
prnewswire.com |
2024-12-02 09:00:00 |
Czytaj oryginał (ang.) |
| PTC Therapeutics Ends Utreloxastat Development After Rare Neurodegenerative Disease Trial Misses Goal, Analyst Maintains Outperform With Focus On Sepiapterin, Huntington's Programs |
On Tuesday, PTC Therapeutics Inc PTCT revealed data from the global Phase 2 placebo-controlled CardinALS study of Utreloxastat in amyotrophic lateral sclerosis patients. |
benzinga.com |
2024-11-27 09:51:49 |
Czytaj oryginał (ang.) |
| PTC Therapeutics Enters into Agreement to Sell Priority Review Voucher for $150 Million |
WARREN, N.J. , Nov. 27, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that it has entered into an agreement to sell its Rare Pediatric Disease Priority Review Voucher (PRV) for $150 million upon the closing of the transaction. |
prnewswire.com |
2024-11-27 09:00:00 |
Czytaj oryginał (ang.) |
| PTC Therapeutics discontinues development of ALS drug after trial failure |
PTC Therapeutics said on Tuesday it is discontinuing the development of its drug for a type of fatal neurodegenerative disease, as it did not meet the main goal in a mid-stage trial. |
reuters.com |
2024-11-26 18:41:10 |
Czytaj oryginał (ang.) |
| PTC Therapeutics Announces Topline Results of CardinALS Trial of Utreloxastat in ALS Patients |
- Study failed to meet primary and secondary efficacy endpoints - WARREN, N.J. , Nov. 26, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the global Phase 2 placebo-controlled CardinALS study did not meet its primary endpoint of slowing disease progression on the composite ALSFRS-R and mortality analysis. |
prnewswire.com |
2024-11-26 18:30:00 |
Czytaj oryginał (ang.) |
| PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
WARREN, N.J. , Nov. 25, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on Nov. 20, 2024, the company approved non-statutory stock options to purchase an aggregate of 18,815 shares of its common stock and 17,995 restricted stock units ("RSUs"), each representing the right to receive one share of its common stock upon vesting, to ten new employees. |
prnewswire.com |
2024-11-25 18:30:00 |
Czytaj oryginał (ang.) |
| US FDA approves PTC Therapeutics' gene therapy for ultra-rare disorder |
The U.S. Food and Drug Administration approved PTC Therapeutics' gene therapy that is administered directly in the brain to treat a potential fatal enzyme deficiency disorder, the company said on Wednesday. |
reuters.com |
2024-11-13 20:09:52 |
Czytaj oryginał (ang.) |
| PTC Therapeutics Announces FDA Approval of AADC Deficiency Gene Therapy |
- First-ever FDA approval for gene therapy directly administered to the brain - - Priority review voucher granted - - Broad label including children and adults - - PTC pioneers new approach for CNS drug delivery - WARREN, N.J., Nov. 13, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today the U.S. Food and Drug Administration (FDA) accelerated approval of its gene therapy for the treatment of AADC deficiency, the first-ever gene therapy approved in the United States that is directly administered to the brain. |
prnewswire.com |
2024-11-13 20:02:00 |
Czytaj oryginał (ang.) |
| PTC Therapeutics, Inc. (PTCT) Q3 2024 Earnings Call Transcript |
PTC Therapeutics, Inc. (NASDAQ:PTCT ) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Jane Hanlon - Associate Director, Investor Relations Matthew Klein - Chief Executive Officer Eric Pauwels - Chief Business Officer Pierre Gravier - Chief Financial Officer Conference Call Participants Rick Bienkowski - Cantor Fitzgerald Eric Joseph - JPMorgan Kelly Shi - Jefferies Michael Riad - Morgan Stanley Brian Abraham - RBC Capital Markets Ellie Merle - UBS Joel Beatty - Baird Sami Corwin - William Blair Peyton Bohnsack - TD Cowen Paul Choi - Goldman Sachs Gena Wang - Barclays Danielle Brill - Raymond James Joseph Schwartz - Leerink Partners Operator Welcome to the PTC Third Quarter 2024 Financial Results Conference Call. At this time all participants are in a listen-only mode. |
seekingalpha.com |
2024-11-08 01:19:42 |
Czytaj oryginał (ang.) |
| PTC Therapeutics (PTCT) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates |
The headline numbers for PTC Therapeutics (PTCT) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals. |
zacks.com |
2024-11-07 21:30:42 |
Czytaj oryginał (ang.) |
| PTC Therapeutics (PTCT) Reports Q3 Loss, Tops Revenue Estimates |
PTC Therapeutics (PTCT) came out with a quarterly loss of $1.39 per share versus the Zacks Consensus Estimate of a loss of $1.54. This compares to loss of $1.76 per share a year ago. |
zacks.com |
2024-11-07 20:30:40 |
Czytaj oryginał (ang.) |